ETMR
MCID: EPN001
MIFTS: 44

Ependymoblastoma (ETMR)

Categories: Cancer diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ependymoblastoma

MalaCards integrated aliases for Ependymoblastoma:

Name: Ependymoblastoma 12 74 52 58 54 15 71
Embryonal Tumor with Abundant Neuropil and True Rosettes 52
Embryonal Tumor with Multilayered Rosettes 52
Neuroectodermal Tumors Primitive 52
Etantr 52
Etmr 52

Characteristics:

Orphanet epidemiological data:

58
ependymoblastoma
Inheritance: Not applicable; Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4794
MeSH 43 D018242
NCIt 49 C4915
SNOMED-CT 67 715901002
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0700367
Orphanet 58 ORPHA251880
UMLS 71 C0700367

Summaries for Ependymoblastoma

MalaCards based summary : Ependymoblastoma, also known as embryonal tumor with abundant neuropil and true rosettes, is related to ewing sarcoma and anaplastic ependymoma, and has symptoms including vomiting and headache. An important gene associated with Ependymoblastoma is NES (Nestin), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Donepezil and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related phenotypes are muscle and nervous system

Wikipedia : 74 Primitive neuroectodermal tumor is a malignant (cancerous) neural crest tumor. It is a rare tumor,... more...

Related Diseases for Ependymoblastoma

Diseases in the Ependymoblastoma family:

Adult Ependymoblastoma

Diseases related to Ependymoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 241, show less)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 31.9 VIM SYP MYCN ENO2
2 anaplastic ependymoma 30.7 VIM SYP GFAP
3 rhabdoid tumor predisposition syndrome 1 30.4 VIM SYP SMARCB1
4 benign ependymoma 30.1 VIM SYP NES GFAP ENO2
5 central nervous system cancer 30.0 SYP SMARCB1 NES MYCN GFAP
6 atypical teratoid rhabdoid tumor 29.8 VIM SYP SMARCB1 LIN28A GFAP
7 ganglioneuroblastoma 29.6 SYP MYCN ENO2
8 melanotic neuroectodermal tumor 29.6 VIM SYP GFAP ENO2
9 astroblastoma 29.0 VIM SYP NES GFAP FOXR2 ENO2
10 medulloepithelioma 29.0 VIM SYP SMARCB1 NES LIN28A GFAP
11 hydrocephalus 28.9 VIM SYP SMARCB1 NGF NES GFAP
12 neuroblastoma 28.8 SYP NGF NES MYCN MET GFAP
13 medulloblastoma 28.3 VIM SYP SMARCB1 NGF NES MYCN
14 pediatric infratentorial ependymoblastoma 12.2
15 adult ependymoblastoma 12.2
16 pediatric cerebral ependymoblastoma 12.2
17 pediatric supratentorial ependymoma 11.4
18 embryonal carcinoma 10.6
19 cellular ependymoma 10.6
20 anaplastic ganglioglioma 10.5 NES GFAP
21 chromosomal triplication 10.5
22 central nervous system immature teratoma 10.5 NES GFAP
23 odontoma 10.5 VIM NES
24 malignant ependymoma 10.4
25 cutaneous leiomyosarcoma 10.4 VIM GFAP
26 primary hepatic neuroendocrine carcinoma 10.4 VIM SYP
27 glomangiomyoma 10.4 VIM SYP
28 extraventricular neurocytoma 10.4 SYP GFAP
29 parachordoma 10.4 VIM GFAP
30 lung combined type small cell carcinoma 10.4 SYP GFAP
31 esophageal adenoid cystic carcinoma 10.4 VIM SYP
32 tanycytic ependymoma 10.4 SYP GFAP
33 chiari malformation 10.4 SYP GFAP
34 tetraploidy 10.3
35 glomangioma 10.3 VIM SYP
36 medullomyoblastoma 10.3 SYP GFAP
37 laryngeal neuroendocrine tumor 10.3 SYP SMARCB1
38 mixed glioma 10.3 NES GFAP
39 binswanger's disease 10.3 SYP GFAP
40 secretory meningioma 10.3 VIM SMARCB1
41 papillary adenoma 10.3 VIM SYP
42 large cell medulloblastoma 10.3 VIM SYP MET
43 angiocentric glioma 10.3 VIM SYP GFAP
44 myoepithelial carcinoma 10.3 VIM SMARCB1 GFAP
45 meningioma, radiation-induced 10.3 VIM SMARCB1 GFAP
46 chordoid meningioma 10.3 VIM SYP GFAP
47 dysembryoplastic neuroepithelial tumor 10.2 SYP NES GFAP
48 myoepithelioma 10.2 VIM SMARCB1 GFAP
49 gliomatosis cerebri 10.2 SYP NES GFAP
50 rare tumor 10.2
51 juvenile pilocytic astrocytoma 10.2 SYP NES GFAP
52 chordoid glioma 10.2 SYP GFAP
53 central epithelioid sarcoma 10.2 VIM SYP SMARCB1
54 epithelioid sarcoma 10.2 VIM SYP SMARCB1
55 vulvar proximal-type epithelioid sarcoma 10.2 VIM SYP SMARCB1
56 osteochondroma 10.2 VIM NES
57 syringoma 10.2 VIM GFAP
58 cerebral degeneration 10.2 SYP NES GFAP
59 cerebral primitive neuroectodermal tumor 10.2 SYP MYCN
60 germ cell and embryonal cancer 10.2 NES MIR371A LIN28A
61 pleomorphic xanthoastrocytoma 10.2 SYP SMARCB1 GFAP
62 toxic encephalopathy 10.2 SYP NGF GFAP
63 ptosis 10.2
64 diffuse midline glioma, h3 k27m-mutant 10.2
65 intraocular medulloepithelioma 10.2
66 dicer1 tumor predisposition 10.1
67 malignant peripheral nerve sheath tumor 10.1 VIM SMARCB1 MET
68 brain stem glioma 10.1 NES MYCN GFAP
69 pick disease of brain 10.1 SYP NGF GFAP
70 hydronephrosis 10.1
71 malignant glioma 10.1
72 rhabdoid cancer 10.1
73 spinal cord ependymoma 10.1
74 intracranial hypertension 10.1
75 brain tumor, childhood 10.1
76 glioma 10.1
77 glial tumor 10.1
78 central nervous system embryonal tumor 10.1
79 sweat gland benign neoplasm 10.1 SMARCB1 GFAP
80 chordoma 10.1 VIM SMARCB1 MET GFAP
81 bednar tumor 10.1 VIM ENO2
82 desmoplastic infantile ganglioglioma 10.1 SYP MYCN GFAP
83 intracranial cysts 10.1 GFAP ENO2
84 congenital epulis 10.0 VIM ENO2
85 epulis 10.0 VIM ENO2
86 infratentorial cancer 10.0 SMARCB1 NES MYCN
87 clear cell meningioma 10.0 VIM SYP SMARCB1 GFAP
88 osteofibrous dysplasia 10.0 VIM MET
89 myxopapillary ependymoma 10.0 VIM SYP SMARCB1 GFAP
90 giant cell glioblastoma 10.0 SYP SMARCB1 NES GFAP
91 ewing sarcoma of bone 10.0 VIM ENO2
92 nodular medulloblastoma 10.0 SYP SMARCB1 MYCN
93 malignant melanocytic neoplasm of the peripheral nerve sheath 10.0 SYP ENO2
94 carcinosarcoma 10.0
95 large cell carcinoma with rhabdoid phenotype 10.0 SMARCB1 ENO2
96 anal neuroendocrine tumor 10.0 SYP ENO2
97 breast neuroendocrine neoplasm 10.0 SYP ENO2
98 sinonasal undifferentiated carcinoma 10.0 SYP ENO2
99 small cell carcinoma of the bladder 10.0 SYP ENO2
100 intracranial primitive neuroectodermal tumor 10.0 SYP ENO2
101 bile duct mucinous adenocarcinoma 10.0 SYP ENO2
102 auditory system benign neoplasm 10.0 SYP ENO2
103 appendix carcinoid tumor 10.0 SYP ENO2
104 auditory system cancer 10.0 SYP ENO2
105 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.0 SYP ENO2
106 cauda equina neoplasm 10.0 SYP ENO2
107 duodenal benign neoplasm 10.0 SYP ENO2
108 nodular prostate 10.0 SYP ENO2
109 ampulla of vater neoplasm 10.0 SYP ENO2
110 urinary bladder small cell neuroendocrine carcinoma 10.0 SYP ENO2
111 ureter small cell carcinoma 10.0 SYP ENO2
112 ossifying fibromyxoid tumor 10.0 VIM ENO2
113 cerebellar liponeurocytoma 10.0 SYP ENO2
114 middle ear adenoma 10.0 SYP ENO2
115 jejunal neoplasm 10.0 SYP ENO2
116 carotid body cancer 10.0 SYP ENO2
117 gallbladder small cell carcinoma 10.0 SYP ENO2
118 pineoblastoma 10.0 SYP GFAP FOXR2
119 gastric small cell carcinoma 9.9 SYP ENO2
120 kidney rhabdoid cancer 9.9 SMARCB1 ENO2
121 sensory organ benign neoplasm 9.9 SYP ENO2
122 myoblastoma 9.9 SYP ENO2
123 pineal parenchymal tumor of intermediate differentiation 9.9 SYP ENO2
124 ovarian large-cell neuroendocrine carcinoma 9.9 SYP ENO2
125 traumatic brain injury 9.9 GFAP ENO2
126 gastric hemangioma 9.9 SYP ENO2
127 lung oat cell carcinoma 9.9 SYP ENO2
128 brain injury 9.9 GFAP ENO2
129 cutaneous ganglioneuroma 9.9 SYP ENO2
130 cervix small cell carcinoma 9.9 SYP ENO2
131 carcinoid tumors, intestinal 9.9 SYP ENO2
132 chondrosarcoma 9.9 VIM MET ENO2
133 orbital cancer 9.9 SYP ENO2
134 primitive neuroectodermal tumor of the cervix uteri 9.9 VIM GFAP ENO2
135 carcinoid syndrome 9.9 SYP ENO2
136 endometrial small cell carcinoma 9.9 SYP ENO2
137 colon neuroendocrine neoplasm 9.9 SYP ENO2
138 nasal cavity olfactory neuroblastoma 9.9 SYP ENO2
139 pulmonary neuroendocrine tumor 9.9 SYP ENO2
140 bladder lateral wall cancer 9.9 SYP ENO2
141 hypertryptophanemia 9.9 NES GFAP
142 small intestine benign neoplasm 9.9 SYP ENO2
143 extraosseous ewing sarcoma 9.9 SYP ENO2
144 endobronchial lipoma 9.9 SYP ENO2
145 dermatofibrosarcoma protuberans 9.9 VIM NES ENO2
146 mediastinal cancer 9.9 SYP ENO2
147 papillary tumor of the pineal region 9.8 VIM SYP ENO2
148 uterus leiomyosarcoma 9.8 SYP ENO2
149 epithelioid leiomyosarcoma 9.8 VIM ENO2
150 retroperitoneal neuroblastoma 9.8 MYCN ENO2
151 extraskeletal ewing sarcoma 9.8 VIM SYP ENO2
152 granulosa cell tumor of the ovary 9.8 VIM SYP ENO2
153 papillary ependymoma 9.8 SYP GFAP ENO2
154 cerebral neuroblastoma 9.8 SYP GFAP ENO2
155 nodular ganglioneuroblastoma 9.8 MYCN ENO2
156 cerebellopontine angle primitive neuroectodermal tumor 9.8 SYP GFAP ENO2
157 horseshoe kidney 9.8 SYP ENO2
158 pineocytoma 9.8 SYP GFAP ENO2
159 glomus tumor 9.8 VIM SYP ENO2
160 olfactory neuroblastoma 9.8 VIM SYP ENO2
161 endobronchial leiomyoma 9.8 SYP GFAP ENO2
162 sertoli cell tumor 9.8 VIM SYP ENO2
163 spinal cord oligodendroglioma 9.8 SYP GFAP ENO2
164 hemangiopericytoma, malignant 9.8 VIM SYP ENO2
165 olfactory nerve neoplasm 9.8 SYP GFAP ENO2
166 cranial nerve malignant neoplasm 9.8 SYP GFAP ENO2
167 cerebellar medulloblastoma 9.8 SYP GFAP ENO2
168 gangliocytoma 9.8 SYP GFAP ENO2
169 spindle cell carcinoma 9.8 VIM SYP ENO2
170 obstructive hydrocephalus 9.8 SYP GFAP ENO2
171 cystic basal cell carcinoma 9.8 SYP ENO2
172 lung benign neoplasm 9.8 SYP MET ENO2
173 cystic teratoma 9.8 SYP GFAP ENO2
174 subleukemic leukemia 9.8 SYP ENO2
175 pineal region teratoma 9.8 SYP SMARCB1 ENO2
176 optic nerve astrocytoma 9.8 SYP SMARCB1 ENO2
177 microcystic adenoma 9.8 SYP ENO2
178 extraosseous chondrosarcoma 9.8 SYP SMARCB1 ENO2
179 ovarian small cell carcinoma 9.8 SYP SMARCB1 ENO2
180 pulmonary sclerosing hemangioma 9.7 SYP ENO2
181 endocrine organ benign neoplasm 9.7 SYP NGF ENO2
182 optic nerve glioma 9.7 VIM NES GFAP ENO2
183 choroid plexus cancer 9.7 SYP SMARCB1 GFAP FOXR2
184 sclerosing hemangioma 9.7 SYP ENO2
185 sarcoma, synovial 9.7 VIM SMARCB1 NES MYCN MET
186 mature teratoma 9.7 SYP MIR371A ENO2
187 paraganglioma 9.7 SYP GFAP ENO2
188 creutzfeldt-jakob disease 9.7 NGF NES GFAP ENO2
189 subependymoma 9.7 SYP NES GFAP ENO2
190 central neurocytoma 9.7 SYP NES GFAP ENO2
191 clear cell ependymoma 9.7 VIM SYP GFAP ENO2
192 alveolar soft part sarcoma 9.6 VIM SYP MET ENO2
193 granular cell tumor 9.6 VIM SYP GFAP ENO2
194 hemangioblastoma 9.6 VIM SYP GFAP ENO2
195 oligodendroglioma 9.6 VIM SYP GFAP ENO2
196 frontal lobe neoplasm 9.6 SYP MYCN ENO2
197 cervical neuroblastoma 9.6 SYP MYCN ENO2
198 adrenal neuroblastoma 9.6 SYP MYCN ENO2
199 neuroma 9.6 SMARCB1 NGF GFAP ENO2
200 extracranial neuroblastoma 9.6 SYP MYCN ENO2
201 prostate neuroendocrine neoplasm 9.6 SYP MYCN ENO2
202 small cell carcinoma 9.6 SYP MYCN ENO2
203 autonomic nervous system benign neoplasm 9.6 SYP MYCN ENO2
204 peripheral nervous system benign neoplasm 9.6 SYP MYCN ENO2
205 mesenchymal chondrosarcoma 9.6 VIM SYP SMARCB1 ENO2
206 bone benign neoplasm 9.6 SYP ENO2
207 cerebrovascular benign neoplasm 9.6 SYP SMARCB1 GFAP ENO2
208 cranial nerve neoplasm 9.6 SYP SMARCB1 GFAP ENO2
209 spinal cancer 9.6 SYP SMARCB1 GFAP ENO2
210 papilloma of choroid plexus 9.6 SYP SMARCB1 GFAP ENO2
211 germ cell cancer 9.6 NES MIR371A LIN28A ENO2
212 chondrosarcoma, extraskeletal myxoid 9.6 SYP SMARCB1 GFAP ENO2
213 glioblastoma multiforme 9.6 SYP NES MYCN MET GFAP
214 meningioma, familial 9.5 SYP SMARCB1 GFAP ENO2
215 malignant teratoma 9.5 SYP MIR371A LIN28A ENO2
216 supratentorial primitive neuroectodermal tumor 9.5 SYP SMARCB1 MYCN MIR520G GFAP
217 neurilemmoma 9.5 VIM SMARCB1 NES GFAP ENO2
218 subependymal giant cell astrocytoma 9.5 VIM SYP NES GFAP ENO2
219 gliosarcoma 9.5 VIM SYP NES GFAP ENO2
220 tuberous sclerosis 9.5 VIM SYP NES GFAP ENO2
221 cerebellum cancer 9.4 SYP MYCN GFAP ENO2
222 central nervous system benign neoplasm 9.4 SYP MYCN GFAP ENO2
223 ganglioneuroma 9.4 SYP MYCN GFAP ENO2
224 askin's tumor 9.4 SYP NGF MYCN ENO2
225 rhabdoid meningioma 9.4 VIM SYP SMARCB1 GFAP ENO2
226 gastrointestinal stromal tumor 9.4 VIM SYP SMARCB1 NES ENO2
227 autonomic nervous system neoplasm 9.4 SYP NGF MYCN ENO2
228 peripheral nervous system neoplasm 9.4 SYP NGF MYCN ENO2
229 skeletal muscle cancer 9.4 SYP SMARCB1 MYCN ENO2
230 muscle cancer 9.4 SYP SMARCB1 MYCN ENO2
231 retinoblastoma 9.2 SYP SMARCB1 MYCN MET ENO2
232 wilms tumor 1 9.2 SYP SMARCB1 MYCN LIN28A ENO2
233 pineal gland cancer 9.1 SYP SMARCB1 GFAP FOXR2 ENO2
234 rhabdomyosarcoma 9.1 VIM SYP NES MYCN MET ENO2
235 cerebrum cancer 9.0 SYP SMARCB1 NES MYCN GFAP ENO2
236 cerebral ventricle cancer 9.0 SYP SMARCB1 NES MYCN GFAP ENO2
237 supratentorial cancer 9.0 SYP SMARCB1 NES MYCN GFAP ENO2
238 ganglioglioma 9.0 SYP SMARCB1 NES MYCN GFAP ENO2
239 teratoma 9.0 VIM SYP SMARCB1 NGF NES GFAP
240 brain cancer 9.0 SYP SMARCB1 NES MYCN GFAP ENO2
241 central nervous system primitive neuroectodermal neoplasm 7.4 SYP SMARCB1 NES MYCN MIR520G MIR518C

Graphical network of the top 20 diseases related to Ependymoblastoma:



Diseases related to Ependymoblastoma

Symptoms & Phenotypes for Ependymoblastoma

UMLS symptoms related to Ependymoblastoma:


vomiting, headache

MGI Mouse Phenotypes related to Ependymoblastoma:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.5 GFAP LIN28A MET MYCN NGF SMARCB1
2 nervous system MP:0003631 9.28 ENO2 GFAP LIN28A MET MYCN NGF

Drugs & Therapeutics for Ependymoblastoma

Drugs for Ependymoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 246, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Ondansetron Approved Phase 3 99614-02-5 4595
3
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
6
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
9
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
10
leucovorin Approved Phase 3 58-05-9 6006 143
11
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
15
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
16
Ifosfamide Approved Phase 3 3778-73-2 3690
17
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
18 Grape Approved Phase 3
19 Cranberry Approved, Investigational Phase 3
20
Daunorubicin Approved Phase 3 20830-81-3 30323
21
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
22
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
23
Histamine Approved, Investigational Phase 3 51-45-6 774
24
Cyproheptadine Approved Phase 3 129-03-3 2913
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27
Camptothecin Experimental Phase 3 7689-03-4
28 Analgesics Phase 3
29 Liver Extracts Phase 3
30 Antiemetics Phase 3
31 Cholinesterase Inhibitors Phase 3
32 Cholinergic Agents Phase 3
33 Emetics Phase 3
34 Cola Phase 3
35 Anesthetics Phase 3
36 Narcotics Phase 3
37 Analgesics, Opioid Phase 3
38 Anesthetics, General Phase 3
39 Anesthetics, Intravenous Phase 3
40 Etoposide phosphate Phase 3
41 Vitamin B Complex Phase 3
42 Immunosuppressive Agents Phase 3
43 Folate Phase 3
44 Folic Acid Antagonists Phase 3
45 Tubulin Modulators Phase 3
46 Antirheumatic Agents Phase 3
47 Vitamin B9 Phase 3
48 Antimitotic Agents Phase 3
49 Micronutrients Phase 3
50 Vitamins Phase 3
51 Antidotes Phase 3
52 Nutrients Phase 3
53 Calcium, Dietary Phase 3
54 Trace Elements Phase 3
55 Protective Agents Phase 3
56
Liposomal doxorubicin Phase 3 31703
57 Antibiotics, Antitubercular Phase 3
58 Immunoglobulins Phase 3
59 Antibodies Phase 3
60 Antibodies, Monoclonal Phase 3
61 topoisomerase I inhibitors Phase 3
62
Isophosphamide mustard Phase 3 0
63 Podophyllotoxin Phase 3 518-28-5
64 Keratolytic Agents Phase 3
65 Dermatologic Agents Phase 3
66 Gastrointestinal Agents Phase 3
67 Neurotransmitter Agents Phase 3
68 Dopamine Agents Phase 3
69 Central Nervous System Stimulants Phase 3
70 Dexmethylphenidate Hydrochloride Phase 3
71 Histamine Antagonists Phase 3
72 Anti-Allergic Agents Phase 3
73
Histamine Phosphate Phase 3 51-74-1 65513
74 Histamine H1 Antagonists Phase 3
75
Calcium Nutraceutical Phase 3 7440-70-2 271
76
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
77
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
78
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
79
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
80
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
81
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
82
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
83
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
84
Talazoparib Approved, Investigational Phase 1, Phase 2 1207456-01-6 135565082
85
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
86
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
87
Levetiracetam Approved Phase 2 102767-28-2 441341
88
Pregabalin Approved, Investigational Phase 2 148553-50-8 5486971
89
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
90
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
91
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
92
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
93
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
94
Olaparib Approved Phase 2 763113-22-0 23725625
95
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 71657455
96
Methoxsalen Approved Phase 2 298-81-7 4114
97
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
98
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
99
afatinib Approved Phase 1, Phase 2 439081-18-2, 850140-72-6 10184653
100
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
101
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
102
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
103
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
104
nivolumab Approved Phase 1, Phase 2 946414-94-4
105
Bevacizumab Approved, Investigational Phase 2 216974-75-3
106
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
107
Pembrolizumab Approved Phase 2 1374853-91-4
108
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
109
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
110
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
111
Iodine Approved, Investigational Phase 2 7553-56-2 807
112
Promethazine Approved, Investigational Phase 2 60-87-7 4927
113
Acetaminophen Approved Phase 2 103-90-2 1983
114
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
115
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
116
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
117
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 6251 453
118
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668